Literature DB >> 29946874

[Bridging anticoagulation in patients receiving vitamin K antagonists : Current status].

S M Schellong1, H Riess2, M Spannagl3, H Omran4, M Schwarzbach5, F Langer6, W Gogarten7, P Bramlage8, R M Bauersachs9,10.   

Abstract

Approximately 30% of patients receiving oral anticoagulation using vitamin K antagonists (VKA) require surgery within 2 years. In this context, a clinical decision on the need and the mode of a peri-interventional bridging with heparin is needed. While a few years ago, bridging was almost considered a standard of care, recent study results triggered a discussion on which patients will need bridging at all. Revisiting the currently available recommendations and study results the conclusion can be drawn that the indications for bridging with heparin must nowadays be taken more narrowly and considering the individual patient risk of bleeding and thromboembolism. Bridging with heparin is only needed in patients with a very high risk of thromboembolism. This overview aims to give guidance for a risk-adapted peri-interventional approach to management of patients with a need for long-term anticoagulation using VKA.

Entities:  

Keywords:  Heparin, low molecular weight; International Normalized Ratio; Perioperative care; Risk, hemorrhage; Risk, thromboembolism

Mesh:

Substances:

Year:  2018        PMID: 29946874     DOI: 10.1007/s00108-018-0447-9

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  20 in total

Review 1.  Regional anaesthesia and antithrombotic agents: recommendations of the European Society of Anaesthesiology.

Authors:  Wiebke Gogarten; Erik Vandermeulen; Hugo Van Aken; Sibylle Kozek; Juan V Llau; Charles M Samama
Journal:  Eur J Anaesthesiol       Date:  2010-12       Impact factor: 4.330

2.  Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  James D Douketis; Alex C Spyropoulos; Frederick A Spencer; Michael Mayr; Amir K Jaffer; Mark H Eckman; Andrew S Dunn; Regina Kunz
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

3.  The HAS-BLED score predicts bleedings during bridging of chronic oral anticoagulation. Results from the national multicentre BNK Online bRiDging REgistRy (BORDER).

Authors:  Heyder Omran; Rupert Bauersachs; Siegfried Rübenacker; Franz Goss; Christoph Hammerstingl
Journal:  Thromb Haemost       Date:  2012-04-26       Impact factor: 5.249

Review 4.  Periprocedural antithrombotic and bridging therapy: recommendations for standardized reporting in patients with arterial indications for chronic oral anticoagulant therapy.

Authors:  A C Spyropoulos; J D Douketis; G Gerotziafas; S Kaatz; T L Ortel; S Schulman
Journal:  J Thromb Haemost       Date:  2012-04       Impact factor: 5.824

5.  Pacemaker or defibrillator surgery without interruption of anticoagulation.

Authors:  David H Birnie; Jeff S Healey; George A Wells; Atul Verma; Anthony S Tang; Andrew D Krahn; Christopher S Simpson; Felix Ayala-Paredes; Benoit Coutu; Tiago L L Leiria; Vidal Essebag
Journal:  N Engl J Med       Date:  2013-05-09       Impact factor: 91.245

6.  Reduced-dose warfarin or interrupted warfarin with heparin bridging for pacemaker or defibrillator implantation: a randomized trial.

Authors:  S Schulman; J S Healey; J D Douketis; J Delaney; C A Morillo
Journal:  Thromb Res       Date:  2014-08-01       Impact factor: 3.944

7.  2014 ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management: The Joint Task Force on non-cardiac surgery: cardiovascular assessment and management of the European Society of Cardiology (ESC) and the European Society of Anaesthesiology (ESA).

Authors:  Steen Dalby Kristensen; Juhani Knuuti; Antti Saraste; Stefan Anker; Hans Erik Bøtker; Stefan De Hert; Ian Ford; Jose Ramón Gonzalez-Juanatey; Bulent Gorenek; Guy Robert Heyndrickx; Andreas Hoeft; Kurt Huber; Bernard Iung; Keld Per Kjeldsen; Dan Longrois; Thomas F Lüscher; Luc Pierard; Stuart Pocock; Susanna Price; Marco Roffi; Per Anton Sirnes; Miguel Sousa-Uva; Vasilis Voudris; Christian Funck-Brentano
Journal:  Eur Heart J       Date:  2014-08-01       Impact factor: 29.983

8.  Surgery and invasive procedures in patients on long-term treatment with direct oral anticoagulants: thrombin or factor-Xa inhibitors. Recommendations of the Working Group on Perioperative Haemostasis and the French Study Group on Thrombosis and Haemostasis.

Authors:  Pierre Sié; Charles M Samama; Anne Godier; Nadia Rosencher; Annick Steib; Juan V Llau; Philippe Van der Linden; Gilles Pernod; Thomas Lecompte; Isabelle Gouin-Thibault; Pierre Albaladejo
Journal:  Arch Cardiovasc Dis       Date:  2011-10-29       Impact factor: 2.340

9.  Perioperative bridging anticoagulation during dabigatran or warfarin interruption among patients who had an elective surgery or procedure. Substudy of the RE-LY trial.

Authors:  James D Douketis; Jeff S Healey; Martina Brueckmann; John W Eikelboom; Michael D Ezekowitz; Mandy Fraessdorf; Herbert Noack; Jonas Oldgren; Paul Reilly; Alex C Spyropoulos; Lars Wallentin; Stuart J Connolly
Journal:  Thromb Haemost       Date:  2014-12-04       Impact factor: 5.249

Review 10.  Systematic review of the influence of enhanced recovery pathways in elective lung resection.

Authors:  Julio F Fiore; Jimmy Bejjani; Kate Conrad; Petru Niculiseanu; Tara Landry; Lawrence Lee; Lorenzo E Ferri; Liane S Feldman
Journal:  J Thorac Cardiovasc Surg       Date:  2015-10-03       Impact factor: 5.209

View more
  1 in total

1.  Inhibition of Platelet Aggregation After Coronary Stenting in Patients Receiving Oral Anticoagulation.

Authors:  Conrad Genz; Ruediger C Braun-Dullaeus
Journal:  Dtsch Arztebl Int       Date:  2021-06-04       Impact factor: 5.594

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.